Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.

To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
Sponsorship
Antitrust
Washington Lawyers’ Committee for Civil Rights and Urban Affairs – 2025 Wiley A. Branton Awards Luncheon
Sponsorship
Antitrust
Axinn Partners Named to WIPR's Leaders 2025 Directory
Awards & Recognitions
Intellectual Property
NJSBA Annual Meeting and Convention 2025
Speaking Engagement
Intellectual Property
Trump’s DOJ Stays the Course in Opposition to Shared Algorithmic Pricing
Byline Articles
Antitrust
Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
Webinar
Intellectual Property